RIPK3 and metabolic dysfunction-associated steatohepatitis: Although targeting RIPK3 is a novel and promising therapeutic approach for NAFLD/NASH and HCC, it is crucial to consider that inhibiting necroptosis should not inadvertently activate other alternative cell death pathways in clinical practice.